STRO
Sutro Biopharma, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-25/100
Last price
14.45
▼ 0.68 (4.49%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
15.14
Prev close
15.13
Day high
15.14
Day low
14.37
Volume
162.79K
Market cap
$239.60M
P/E (TTM)
—
52W range
7.15 – 43.85
Day trading desk
Gap from prior close
+0.07%
Prior close 15.13
VWAP
14.53
-0.57% from price
Relative volume
1.02×
Normal
Session range
5.36%
14.37 – 15.14
Position in range
10%
Near session low
ATR (14D)
0.95
6.60% of price
Prior day high
15.46
PDH
Prior day low
14.27
PDL
Bid / ask spread
—
Quote not published
Session volume
303.42K
Avg 296.30K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-10.25%
-12.2%
1M
-28.00%
-29.2%
3M
-54.62%
-59.1%
6M
-43.80%
-62.0%
YTD
+24.89%
+10.6%
1Y
+58.79%
+42.4%
3Y
-58.36%
-140.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on STRO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
374.40K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 18, 26 | GERBER HANS-PETER PH.D. Officer |
— | 3.75K | — | Direct |
| Jun 2, 26 | CHOW GREGORY KWOK LEE Chief Financial Officer |
— | 2.50K | — | Direct |
| Mar 4, 26 | CHUNG JANE Chief Executive Officer |
— | 788 | — | Direct |
| Mar 4, 26 | PAULING DAVID J.D. General Counsel |
— | 675 | — | Direct |
| Mar 2, 26 | CHUNG JANE Chief Executive Officer |
— | 10.94K | — | Direct |
| Mar 2, 26 | GERBER HANS-PETER PH.D. Officer |
— | 3.97K | — | Direct |
| Mar 2, 26 | PAULING DAVID J.D. General Counsel |
— | 3.70K | — | Direct |
| Dec 12, 25 | CHUNG JANE Chief Executive Officer |
— | 2.50K | — | Direct |
| Oct 15, 25 | MATSUI CONNIE L Director |
BUY | 50.00K | $39.95K | Direct |
| Oct 15, 25 | CHOW GREGORY KWOK LEE Chief Financial Officer |
BUY | 19.75K | $16.00K | Direct |
| Oct 15, 25 | CHUNG JANE Chief Executive Officer |
BUY | 12.50K | $10.01K | Direct |
| Oct 15, 25 | GERBER HANS-PETER PH.D. Officer |
BUY | 17.00K | $13.61K | Direct |
| Oct 15, 25 | PAULING DAVID J.D. General Counsel |
BUY | 12.50K | $9.99K | Direct |
| Sep 18, 25 | GERBER HANS-PETER PH.D. Officer |
— | 37.50K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALBINI EDWARD C |
Chief Financial Officer | 160.81K | Conversion of Exercise of derivative security |
BORGMAN ANNE ELIZABETH |
Officer | 97.45K | Conversion of Exercise of derivative security |
CHUNG JANE |
Chief Executive Officer | 21.29K | Conversion of Exercise of derivative security |
FITZPATRICK LINDA A. |
Officer | 130.13K | Conversion of Exercise of derivative security |
GERBER HANS-PETER PH.D. |
Officer | 12.37K | Conversion of Exercise of derivative security |
LEYMAN BARBARA |
Officer | 16.06K | Conversion of Exercise of derivative security |
MATSUI CONNIE L |
Director | 50.00K | Purchase |
NEWELL WILLIAM J |
Chief Executive Officer | 409.06K | Conversion of Exercise of derivative security |
PAULING DAVID J.D. |
General Counsel | 9.75K | Conversion of Exercise of derivative security |
SRINIVASAN VENKATESH |
Officer | 53.69K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$239.60M
Enterprise value$86.03M
Revenue (TTM)$45.70M
Gross profit$-99.04M
EBITDA$-125.80M
Net income$-180.64M
EPS (TTM)$-17.28
Free cash flow$-100.76M
Total cash$164.35M
Total debt$10.78M
Book value / share$-6.23
Shares outstanding16.58M
Float10.76M
Short % of float12.56%
Dividend yield0.00%
Beta (5Y)1.50
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.33
PEG ratio—
Price / sales—
Price / book—
EV / revenue1.88
EV / EBITDA-0.68
Gross margin-216.71%
Operating margin-301.73%
Profit margin0.00%
Return on equity—
Return on assets-36.08%
Debt / equity—
Current ratio3.32
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $102.48M | $62.04M | $153.73M | $67.77M | +65.2% |
| Operating revenue | $102.48M | $62.04M | $153.73M | $67.77M | +65.2% |
| Research & development | $166.42M | $252.04M | $180.43M | $137.17M | -34.0% |
| Selling, general & admin | $41.02M | $48.45M | $62.58M | $59.54M | -15.3% |
| Total operating expense | $207.44M | $300.50M | $243.01M | $196.72M | -31.0% |
| Operating income | -$104.95M | -$238.45M | -$89.28M | -$128.94M | +56.0% |
| Net interest income | -$32.81M | $13.36M | -$9.24M | $109.00K | -345.7% |
| Pre-tax income | -$191.18M | -$225.10M | -$88.60M | -$116.70M | +15.1% |
| Tax provision | -$93.00K | $2.36M | $18.19M | $2.50M | -103.9% |
| Net income | -$191.09M | -$227.46M | -$106.79M | -$119.20M | +16.0% |
| Net income to common | -$191.09M | -$227.46M | -$106.79M | -$119.20M | +16.0% |
| Basic EPS | -22.49 | -29.40 | -17.80 | -23.50 | +23.5% |
| Diluted EPS | -22.49 | -29.40 | -17.80 | -23.50 | +23.5% |
| EBIT | -$149.12M | -$194.03M | -$64.85M | -$113.36M | +23.1% |
| EBITDA | -$141.79M | -$186.81M | -$58.03M | -$107.67M | +24.1% |
| Basic shares | 8.50M | 7.74M | 6.02M | 5.07M | +9.8% |
| Diluted shares | 8.50M | 7.74M | 6.02M | 5.07M | +9.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $58.13M | $190.30M | $69.27M | $47.25M | — | -69.5% |
| Cash & short-term investments | $141.43M | $316.89M | $375.62M | $334.36M | — | -55.4% |
| Accounts receivable | $3.98M | $8.62M | $36.08M | $7.12M | — | -53.8% |
| Total current assets | $150.93M | $343.31M | $421.54M | $353.15M | — | -56.0% |
| Property, plant & equipment | $21.55M | $35.87M | $44.76M | $51.06M | — | -39.9% |
| Total assets | $173.83M | $387.21M | $470.74M | $406.94M | — | -55.1% |
| Total current liabilities | $75.13M | $131.89M | $93.75M | $66.55M | — | -43.0% |
| Current debt | — | — | $4.06M | $12.50M | $9.38M | — |
| Long-term debt | — | — | — | $3.77M | $15.74M | — |
| Total debt | $15.67M | $23.15M | $33.63M | $50.43M | — | -32.3% |
| Total liabilities | $306.28M | $342.61M | $321.09M | $189.90M | — | -10.6% |
| Retained earnings | -$977.96M | -$786.87M | -$559.41M | -$452.62M | — | -24.3% |
| Shareholder equity | -$132.45M | $44.60M | $149.65M | $217.05M | — | -397.0% |
| Working capital | $75.79M | $211.42M | $327.80M | $286.61M | — | -64.1% |
| Net tangible assets | -$132.45M | $44.60M | $149.65M | $217.05M | — | -397.0% |
| Shares issued | 8.58M | 8.25M | 6.10M | 5.75M | — | +4.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$191.09M | -$227.46M | -$106.79M | -$119.20M | — | +16.0% |
| Depreciation & amortisation | $7.32M | $7.22M | $6.82M | $5.69M | — | +1.5% |
| Stock-based compensation | $14.01M | $24.69M | $24.91M | $26.30M | — | -43.3% |
| Change in working capital | -$50.40M | $8.90M | -$34.38M | $104.41M | — | -666.3% |
| Operating cash flow | -$177.23M | -$191.54M | -$111.62M | $3.55M | — | +7.5% |
| Capital expenditure | -$1.70M | -$3.10M | -$4.32M | -$7.86M | — | +45.3% |
| Investing cash flow | $45.01M | $218.51M | -$3.92M | -$35.02M | — | -79.4% |
| Share buybacks | — | — | $0 | $0 | -$7.00K | — |
| Financing cash flow | $44.00K | $94.05M | $137.55M | $48.31M | — | -100.0% |
| Free cash flow | -$178.93M | -$194.64M | -$115.93M | -$4.31M | — | +8.1% |
| End cash position | $58.99M | $191.16M | $70.14M | $48.13M | — | -69.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $9.84M | $14.52M | $11.65M | $9.69M | $63.74M | — | -32.3% |
| Operating revenue | $9.81M | $14.52M | $11.65M | $9.69M | $63.65M | — | -32.4% |
| Research & development | $31.70M | $36.55M | $36.64M | $39.85M | $38.33M | — | -13.3% |
| Selling, general & admin | $7.83M | $7.58M | $8.66M | $8.74M | $10.34M | — | +3.3% |
| Total operating expense | $39.53M | $44.14M | $45.30M | $48.59M | $48.67M | — | -10.4% |
| Operating income | -$29.69M | -$29.61M | -$33.66M | -$38.90M | $15.08M | — | -0.2% |
| Net interest income | -$8.64M | -$8.84M | -$8.79M | -$8.40M | -$8.17M | — | +2.3% |
| Pre-tax income | -$38.53M | -$38.50M | -$46.84M | -$56.86M | -$11.52M | — | -0.1% |
| Tax provision | $1.00K | -$15.00K | -$82.00K | $0 | -$18.00K | — | +106.7% |
| Net income | -$38.53M | -$38.48M | -$46.76M | -$56.86M | -$11.50M | — | -0.1% |
| Net income to common | -$38.53M | -$38.48M | -$46.76M | -$56.86M | -$11.50M | — | -0.1% |
| Basic EPS | -2.33 | -2.94 | — | -6.70 | -1.40 | -9.08 | +20.7% |
| Diluted EPS | -2.33 | -2.94 | — | -6.70 | -1.40 | -9.08 | +20.7% |
| EBIT | -$28.16M | -$28.02M | -$36.52M | -$46.45M | -$826.00K | — | -0.5% |
| EBITDA | -$26.90M | -$26.74M | -$34.89M | -$44.55M | $1.07M | — | -0.6% |
| Basic shares | 16.57M | 13.08M | — | 8.49M | 8.46M | 8.36M | +26.7% |
| Diluted shares | 16.57M | 13.08M | — | 8.49M | 8.46M | 8.36M | +26.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $54.34M | $73.68M | $58.13M | $65.93M | $64.03M | -26.3% |
| Cash & short-term investments | $164.35M | $202.56M | $141.43M | $167.59M | $205.13M | -18.9% |
| Accounts receivable | $5.80M | $12.48M | $3.98M | $3.92M | $8.00M | -53.6% |
| Total current assets | $175.65M | $220.97M | $150.93M | $182.11M | $231.63M | -20.5% |
| Property, plant & equipment | $16.82M | $19.07M | $21.55M | $26.69M | $29.82M | -11.8% |
| Total assets | $194.46M | $241.99M | $173.83M | $209.66M | $262.36M | -19.6% |
| Total current liabilities | $52.90M | $70.81M | $75.13M | $71.89M | $74.25M | -25.3% |
| Total debt | $10.78M | $13.63M | $15.67M | $17.66M | $19.59M | -20.9% |
| Total liabilities | $297.78M | $308.88M | $306.28M | $296.93M | $294.47M | -3.6% |
| Retained earnings | -$1.05B | -$1.02B | -$977.96M | -$931.19M | -$874.34M | -3.8% |
| Shareholder equity | -$103.32M | -$66.89M | -$132.45M | -$87.27M | -$32.11M | -54.5% |
| Working capital | $122.75M | $150.16M | $75.79M | $110.22M | $157.38M | -18.3% |
| Net tangible assets | -$103.32M | -$66.89M | -$132.45M | -$87.27M | -$32.11M | -54.5% |
| Shares issued | 16.58M | 16.57M | 8.58M | 8.51M | 8.47M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$38.53M | -$38.48M | -$46.76M | -$56.86M | -$11.50M | — | -0.1% |
| Depreciation & amortisation | $1.26M | $1.28M | $1.62M | $1.90M | $1.90M | — | -1.3% |
| Stock-based compensation | $2.01M | $1.56M | $1.66M | $1.55M | $5.26M | — | +28.7% |
| Change in working capital | -$13.78M | -$16.94M | $4.68M | $4.65M | -$50.58M | — | +18.7% |
| Operating cash flow | -$38.29M | -$42.26M | -$26.43M | -$38.19M | -$44.72M | — | +9.4% |
| Capital expenditure | — | -$11.00K | -$184.00K | -$251.00K | -$86.00K | -$1.17M | — |
| Investing cash flow | $19.36M | -$45.26M | $18.70M | $39.99M | $2.58M | — | +142.8% |
| Financing cash flow | -$418.00K | $103.08M | -$64.00K | $102.00K | -$60.00K | — | -100.4% |
| Free cash flow | -$38.29M | -$42.27M | -$26.62M | -$38.44M | -$44.81M | — | +9.4% |
| End cash position | $55.19M | $74.54M | $58.99M | $66.78M | $64.88M | — | -26.0% |
Options analytics
Put / call volume
0.09
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
12.50
-13.5% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
+18.7%
Puts bid over calls
Call volume
44
Contracts, this expiry
Put volume
4
Contracts, this expiry
Heaviest call OI
15.00
0 contracts
Heaviest put OI
12.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -2.29 | -2.31 | -1.0% |
| Mar 2026 | -3.22 | -2.94 | +8.6% |
| Dec 2025 | -4.43 | -4.88 | -10.2% |
| Sep 2025 | -3.55 | -5.57 | -57.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -2.07 | 3 | $13.62M | +40.5% |
| Next quarter | -2.36 | 3 | $13.59M | +16.7% |
| Current year | -7.77 | 3 | $51.55M | -49.7% |
| Next year | -6.21 | 4 | $31.59M | -38.7% |
Analyst targets & ownership
Mean target$47.23
High target$61.00
Low target$10.00
Implied upside226.86%
Analyst count13
ConsensusSTRONG BUY
Strong buy / Buy3 / 10
Hold0
Sell / Strong sell0 / 1
Held by insiders2.26%
Held by institutions98.91%
Institutions holding145
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
15.66
-7.70% from price
SMA 20
16.10
-10.24% from price
SMA 50
19.84
-27.16% from price
SMA 100
24.21
-40.32% from price
SMA 200
23.03
-37.25% from price
EMA 12
15.77
-8.37% from price
EMA 26
17.12
-15.62% from price
EMA 50
19.39
-25.48% from price
RSI (14)
23.9
Oversold
MACD (12,26,9)
-1.35
Hist 0.11
ATR (14)
0.95
6.60% of price
Realised vol 30D
43.7%
Annualised
Bollinger upper
17.85
20, 2σ
Bollinger lower
14.35
20, 2σ
50 / 200 cross
Death
19.84 vs 23.03
Trend bias
Below 200
-37.25%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.19
More volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
43.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-64.7%
Peak to trough
Max drawdown 5Y
-97.8%
Peak to trough
ATR 14
0.95
6.60% of price
Beta (reported)
1.50
5Y monthly, from filing
Short interest
Shares short
2.08M
Prior 1.86M
Change vs prior
+11.9%
Shorts adding
% of float
12.56%
Elevated
% of shares out
12.52%
Against total outstanding
Days to cover
7.4
Crowded exit
Float
10.76M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Aug 13, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| May 28, 26 | Barclays | INITIATED | — | Overweight |
| May 15, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| May 15, 26 | Wedbush | UPGRADE | Neutral | Outperform |
| May 15, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 30, 26 | Mizuho | INITIATED | — | Outperform |
| Apr 23, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Apr 17, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Apr 7, 26 | Leerink Partners | INITIATED | — | Outperform |
| Mar 25, 26 | Deutsche Bank | MAINTAINED | Buy | Buy |
| Mar 24, 26 | Wells Fargo | UPGRADE | Equal-Weight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:10
Split dateDec 3, 2025
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-06-08
Periodic Financial Reports
10-Q · 2026-05-14
Annual Report to Shareholders
ARS · 2026-04-22
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-03-30
Periodic Financial Reports
10-K · 2026-03-23
Corporate Changes & Voting Matters
8-K · 2026-02-10
Corporate Changes & Voting Matters
8-K · 2025-12-17
Headlines
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
GlobeNewswire · 8d ago
STRO Stock Plummets 15% — What Drove The Selloff?
Stocktwits · 55d ago
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
GlobeNewswire · 56d ago
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 57d ago
SpaceX upgraded, Trade Desk downgraded: Wall Street's top analyst calls
The Fly · 61d ago
Here Are Friday’s Top Wall Street Analyst Research Calls: Baker Hughes, Etsy, HubSpot, Instacart, JetBlue, Roku, SpaceX, Tower Semiconductor, Trade Desk, and More
24/7 Wall St. · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.